Prevention of postmenopausal bone loss with exchange for short-term HRT for 1α-hydroxycholecalciferol

Maturitas

Volumn 45, Issue 2, 2003, Pages 119-127

  Ushiroyama, Takahisa ^a   Ikeda, Atsushi ^a   Sakai, Masahiro ^a   Higashiyama, Toshihiro ^a   Ueki, Minoru ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

1 Hydroxycholecalciferol; HRT; Osteopenia; Postmenopause; Vertebral bone mineral density

Indexed keywords

ALFACALCIDOL; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; OSTEOCALCIN; PROCOLLAGEN C PROTEINASE; 1-HYDROXYCHOLECALCIFEROL; AMINO ACID; HYDROXYCOLECALCIFEROL; MEDROXYPROGESTERONE; PYRIDINOLINE;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OSTEOPENIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; VERTEBRA; ESTROGEN THERAPY; EVALUATION; LUMBAR VERTEBRA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RADIODENSITOMETRY; RADIOGRAPHY; URINE;

EQUIDAE;

ADMINISTRATION, ORAL; AMINO ACIDS; BONE DENSITY; DENSITOMETRY, X-RAY; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; LUMBAR VERTEBRAE; MEDROXYPROGESTERONE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0142030190     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00130-0     Document Type: Article

References (36)

1. Melton L.J., Kan S.H., Frye M.A. Epidemiology of vertebral fractures in women. Am. J. Epidemiol. 129:1989;1000-1011.
2. Cumming S.R., Kelsey J.L., Nevitt M.C., O'Dowd K.J. Epidemiology of osteoporotic fractures. Epidemiol. Rev. 7:1985;17-208.
3. Henry D., Robertson J., O'Connell D. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1997 and 1995. Climacteric. 1:1998;92-111.
4. Macedo J.M., Macedo C.R., Elkis H. Meta-analysis about efficacy of anti-resorptive drugs in postmenopausal osteoporosis. J. Clin. Pharm. Therap. 23:1998;345-352.
5. Doren M., Samsoie G. Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995. Hum. Reprod. Upd. 6:2000;419-426.
6. Byers T., Cyran L., Davis K., Prindiville S. Hormone replacement therapy after breast cancer: how shall we do no harm? Cancer Pract. 6:1998;296-298.
7. Wren B.G., Brown L. Compliance with hormone replacement therapy. Maturitas. 13:1991;17-21.
8. Shelley J.M., Smith A., Dudley E., Dennerstein L. Use of hormone replacement therapy by Melbourne women. Aust. J. Public Health. 19:1995;387-392.
9. Ravnikar V.A. Compliance with hormone therapy. Am. J. Obstet. Gynecol. 156:1987;1332-1334.
10. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas. 20:1995;91-99.
11. Mattson L.A., Stadberg E., Milsom I. Management of hormone replacement therapy; the Swedish experience. Eur. J. Obstet. Gynecol. Reprod. Biol. 64:1996;S3-S5.
12. Guillemin M.N. Managing menopause: a critical feminist engagement. Scand. J. Public Health. 27:1999;273-278.
13. Kumar R., Cohen W.R., Silva P., Epstein F.H. Elevated 1,25-dihydroxyvitamin D plasma levels in normal human pregnancy and lactation. J. Clin. Invest. 63:1979;342-344.
14. Chesney R.W., Rosen J., Hamstra A., DeLuca H.F. Serum 1-25-dihydroxyvitamin D levels in normal children and in vitamin D disorders. Am. J. Dis. Child. 134:1980;135-139.
15. Ushiroyama T., Okamura S., Ikeda A., Ueki M. Efficacy of ipriflavone and 1α vitamin D therapy for the cessation of vertebral bone loss. Int. J. Gynecol. Obstet. 48:1995;283-288.
16. Aloia J.F., Vaswani A., Yeh J.K., Ellis K., Yasumura S., Cohn S.H. Calcitriol in the treatment of postmenopausal osteoporosis. Am. J. Med. 84:1988;401-408.
17. Orimo H., Shiraki M., Hayashi T., Nakamura T. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1(OH) vitamin D3. Bone Miner. 3:1987;47-52.
18. Ott S.M., Chesnut C.H. III. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann. Intern. Med. 110:1989;267-274.
19. Chen J.T., Shiraki M., Hasumi K., Tanaka N., Katase K., Kato T., Hirai Y., Nakamura T., Ogata E. 1-α-hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone. 20:1997;557-562.
20. Gurlek A., Bayraktar M., Gedik O. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study. Calcif. Tissue Int. 61:1997;39-43.
21. Greene J.G. Constructing a standard climacteric scale. Maturitas. 29:1998;25-31.
22. Ushiroyama T., Okamura S., Sugimoto O. Bone metabolism in patients with physiological menopause and oophorectomy - cross-sectional study (in Japanese). Acta Obstet. Gynaecol. Jpn. 7:1993;695-699.
23. Eyre D.R., Dickson I.R., Van Ness K.P. Collagen cross-linking amino acids. Enzymology. 144:1987;115-139.
24. Eyre D.R., Dickson I.R., Van Ness K.P. Collagen cross-linking in human bone and articular cartilage. Age-related changes in the content of mature hydroxypyridinium residues. Biochem. J. 252:1988;495-500.
25. Cardona J.M., Pastor E. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis; a meta-analysis of published clinical trials. Osteoporosis Int. 7:1997;165-174.
26. Juby A. Managing elderly people's osteoporosis. Why? Who? How? Can. Fam. Phys. 45:1999;1526-1536.
27. Buchs N., Helg C., Collao C., Chapuis B., Slosman D., Bonjour J.P., Rizzoli R. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss. Osteoporos Int. 12:2001;880-886.
28. Stephen A.B., Wallace W.A. The management of osteoporosis. J. Bone Jt. Surg. Br. 83:2001;316-323.
29. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 44:2001;1496-1503.
30. Heikkinen A., Parviainen M.T., Tuppurainen M.T., Niskanen L., Komulainen M.H., Saarikoski S. Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. Calcif. Tissue Int. 62:1998;26-30.
31. Tuppurainen M.T., Komulainen M., Kroger H., Honkanen R., Jurvelin J., Puntila E., Heikkinen A.M., Alhava E., Saarikoski S. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen? Osteororos Int. 8:1998;32-38.
32. Komulainen M.H., Kroger H., Tuppurainen M.T., Heikkinen A.M., Alhava E., Honkanen R., Saarikoski S. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas. 31:1998;45-54.
33. Recker R.R., Davies K.M., Dowd R.M., Heaney R.P. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann. Intern. Med. 130:1999;897-904.
34. Gallagher J.C. Role of estrogens in the management of postmenopausal bone loss. Rheum. Dis. Clin. North Am. 27:2001;143-162.
35. Cortet B., Bera-Louville A., Gauthier P., Gauthier A., Marchandise X., Delcambre B. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. Effect of adding hormone replacement therapy. Jt. Bone Spine. 68:2001;410-415.
36. Nimit T., Unnop J., Krasean P., Sukanya C., Kobchitt L.K. Climacteric: concept, consequence and care. J. Med. Assoc. Thai. 85:(Suppl.):2002;S1-S15.